Renal cell carcinoma (RCC) is the third most common urologic malignancy. First symptoms are usually unspecific and belated causing the stages to be high when diagnosed. As compensation, incidental detection of RCC by abdominal imaging techniques for other medical purposes is a reality that favours a decrease in the stage of new diagnosed tumours. Therefore, identifying novel predictive biomarkers for diagnosis, progression and prognosis of RCC is fundamental.
To date, several studies have demonstrated that microRNAs (miRNAs) play a role in the particular scenario of urologic tumors, and alterations at miRNA level are involved in the initiation, progression and metastases formation of renal cancer. In the present review, we have summarized the up‑to‑date preliminary clinical works on the role of urinary miRNA profiling in RCC, including an evaluation of its value as a potential biomarker for diagnosis, prognosis and follow up of RCC patients.
Current urology reports. 2020 Mar 13*** epublish ***
Julia Oto, Emma Plana, José Vicente Sánchez-González, Jorge García-Olaverri, Álvaro Fernández-Pardo, Francisco España, Manuel Martínez-Sarmiento, César D Vera-Donoso, Silvia Navarro, Pilar Medina
Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute of Hospital La Fe, Fernando Abril Martorell 106, 46026, Valencia, Spain., Department of Urology, La Fe Hospital, Fernando Abril Martorell 106, 46026, Valencia, Spain., Department of Urology, Hospital de Cruces, Baracaldo, Plaza de Cruces, S/N, 48903, Baracaldo, Vizcaya, Spain., Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Medical Research Institute of Hospital La Fe, Fernando Abril Martorell 106, 46026, Valencia, Spain. .